

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. – 11. (Canceled)

12. (Currently amended) A method for improving an Adenovirus vector-producing cell's resistance to apoptosis during Adenovirus vector production, the method comprising:

(a) providing a ~~first~~ polynucleotide ~~sequence~~ comprising a viral or non-viral promoter operably linked to a polynucleotide sequence encoding p21, and contacting the ~~first~~ polynucleotide ~~sequence~~ comprising the viral or nonviral promoter operably coupled to p21 with a cell competent to produce Adenovirus vector DNA,

(b) providing a ~~second~~ polynucleotide sequence comprising the Adenovirus vector to be produced, and contacting the ~~second~~ polynucleotide ~~sequence~~ comprising the Adenovirus vector with the cell of step (a),

and

(c) maintaining the polynucleotide-contacted ~~Adenovirus vector-producing cell~~ competent to produce Adenovirus vector under culture conditions that are conducive to the cellular expression of p21,

and wherein the ~~vector-producing cell's~~ p21 expression provides to the Adenovirus vector producing cell improved resistance to apoptosis during vector production.

13. (Currently amended) A method for preparing Adenovirus vector, comprising:

(a) providing a ~~first~~ polynucleotide ~~sequence~~ comprising a viral or non-viral promoter operably linked to a polynucleotide sequence encoding p21, and contacting the ~~first~~ polynucleotide ~~sequence~~ comprising the viral or nonviral

promoter operably coupled to p21 with a cell competent to produce Adenovirus vector DNA,

(b) providing a polynucleotide sequence comprising the Adenovirus vector to be produced, and contacting the ~~second polynucleotide sequence~~ comprising the Adenovirus vector with the cell of step (a), and

(c) ~~incubating~~ maintaining the polynucleotide-contacted Adenovirus ~~vector-producing cell~~ in competent to produce Adenovirus vector-under culture conditions that are conducive to synthesis of p21 protein and production of the Adenovirus vector DNA the cellular expression of p21, and wherein the p21 expression provides to the Adenovirus vector producing cell improved resistance to apoptosis during vector production.

14. (Currently amended) The method of claim 12 comprising utilizing a constitutive promoter operatively coupled to the ~~nucleotide sequence~~ polynucleotide encoding p21,

15. (Currently amended) The method of claim 12 comprising utilizing a regulatable promoter operatively coupled to the ~~nucleotide sequence~~ polynucleotide encoding p21.

16. (Currently amended) The method of claim 12, wherein the ~~Adenovirus vector-producing cell competent to produce Adenovirus vector DNA~~ has been stably transfected with the ~~first~~ polynucleotide ~~sequence~~-encoding p21 prior to carrying out step (c).

17. (Canceled).

18. (Currently amended) The method of claim 12 wherein the ~~first~~ polynucleotide sequence encoding p21 is in a form selected from the group consisting of naked DNA, viral vectors, and nonviral vectors.

19. (New) The method of claim 12, wherein the viral or non-viral promoter operably linked to a polynucleotide sequence encoding p21 and the polynucleotide sequence comprising the Adenovirus vector to be produced, comprise physically separate polynucleotides.

20. (New) The method of claim 12, wherein the viral or non-viral promoter operably linked to a polynucleotide sequence encoding p21 and the polynucleotide sequence comprising the Adenovirus vector to be produced, comprise a single linked polynucleotide.